Boehringer Ingelheim (BI), the Germany-based pharmaceutical firm, is set to close its Consanas Rehabilitation stroke care unit in China, despite ongoing efforts to develop innovative treatments for the disease. This move follows disappointing performance metrics, with only 11.5% of stroke patients in China receiving rehabilitative treatment within a week and 42.4% not receiving any post-stroke rehabilitation.
BI initially entered the Chinese stroke care market through a partnership with Shanghai International Medical Center (SIMC) in November 2017, leading to the opening of the SMIC Consanas rehabilitation center in March 2018. The company also collaborated with the Columbia China hospital group and formed partnerships with Zhongan Insurance for online care services in 2021, as well as the Wenjiang district government in Chengdu to establish a rehab medical center in November 2022. However, the business did not meet expectations.
The Consanas team will be dismissed once all existing patients are served, with operations and services ceasing on April 1, 2024. This includes shutting down all related accounts, such as the official Consanas website and WeChat accounts. The Consanas Cloud doctor and patient apps will remain available for current patients until June 30, 2024.- Flcube.com
